<SEC-DOCUMENT>0001493152-22-019857.txt : 20220719
<SEC-HEADER>0001493152-22-019857.hdr.sgml : 20220719
<ACCEPTANCE-DATETIME>20220719171534
ACCESSION NUMBER:		0001493152-22-019857
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220719
DATE AS OF CHANGE:		20220719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256850
		FILM NUMBER:		221092205

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)<BR>
Registration No. 333-256850</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Prospectus Supplement dated November 19, 2021 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
Prospectus dated October 22, 2021)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="form424b5_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to $9,584,554</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement amends and supplements the information in the prospectus, dated October 22, 2021, filed with the Securities and
Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-256850), as previously supplemented by our prospectus
supplement dated November 19, 2021 (the &ldquo;Prior Prospectus&rdquo;), relating to the offer and sale of up to $150,000,000 of shares
of our common stock, pursuant to the Open Market Sale Agreement<SUP>SM</SUP>, as amended (the &ldquo;Sale Agreement&rdquo;), we previously
entered into with Jefferies LLC (&ldquo;Jefferies&rdquo;). This prospectus supplement should be read in conjunction with the Prior Prospectus,
and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained
in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with,
the Prior Prospectus and any future amendments or supplements thereto. Through July 15, 2022, we have sold 6,758,744 shares of our common
stock for aggregate gross proceeds of approximately $25.8 million in accordance with the Sale Agreement under the Prior Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are filing this prospectus supplement to amend the Prior Prospectus because we are now subject to General Instruction I.B.6. of Form
S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus
are a part. After giving effect to these limitations and the current public float of our common stock, and after giving effect to the
terms of the Sale Agreement, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $9,584,554
under the Sale Agreement. If our public float increases such that we may sell additional amounts under the Sale Agreement and the registration
statement of which this prospectus supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to
making additional sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;ABEO.&rdquo; The aggregate market value of our common stock
held by non-affiliates as of July 11, 2022 pursuant to General Instruction I.B.6 of Form S-3 is $28,753,662, which was calculated based
on 5,171,522 shares of our common stock outstanding held by non-affiliates and at a price of $5.56 per share, the closing price of our
common stock on July 11, 2022. As of the date hereof, we have not offered or sold any securities pursuant to General Instruction I.B.6.
of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. As a result of the limitations of General
Instruction I.B.6. of Form S-3, and in accordance with the terms of the Sales Agreement, we are registering the offer and sale of shares
of our common stock having an aggregate offering price up to $9,584,554 from time to time through Jefferies. In addition, we have
agreed to reimburse the Agent for fees and disbursements paid to its legal counsel, in an amount not to exceed $50,000, in connection
with this prospectus supplement and, upon the occurrence of certain events specified in the Sale Agreement, up to $15,000 in connection
with each such specified event. In accordance with FINRA Rule 5110, these reimbursed fees and expenses are deemed sales compensation
for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves significant risks. Please see &ldquo;Risk Factors&rdquo; beginning on page S-4 of the Prior Prospectus and
in the documents incorporated by reference into the Prior Prospectus and in our most recent Annual Report on Form 10-K and in our most
recently Quarterly Reports on Form 10-Q, and any amendments thereto, which are incorporated by reference into the Prior Prospectus, and
under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus
supplement and the Prior Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common
stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of the Prior Prospectus, this prospectus supplement or the accompanying prospectus. Any representation
to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jefferies
LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is July 19, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" - # 2(  A$! Q$!_\0
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
